Skip to main content
Clinical Trials/NCT02340143
NCT02340143CompletedNot Applicable

Assessing Early Behavioral Indicators of Formula Tolerance

Mead Johnson Nutrition1 site in 1 country71 target enrollmentStarted: January 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
71
Locations
1
Primary Endpoint
Infant Behavior Diary

Study Overview

Brief Summary

The study is intended to assess the amount of crying and fussiness in infants fed an infant formula containing probiotics.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
14 Days to 28 Days (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Singleton at birth
  • •Term infant with birth weight of 2500 g or more
  • •Crying or fussing for 3 or more hours per day
  • •Consuming mostly infant formula
  • •Signed Informed Consent and Protected Health Information authorization

Exclusion Criteria

  • •Current use of extensively hydrolyzed or amino acid infant formula
  • •Planned use of probiotics during the study
  • •History of underlying metabolic or chronic disease, congenital malformation, or immunocompromised
  • •Enrollment in another interventional clinical research study

Arms & Interventions

Control

Active Comparator

Marketed partially hydrolyzed cow's milk protein infant formula

Intervention: Control (Other)

Investigational

Experimental

Partially hydrolyzed cow's milk infant formula with a probiotic

Intervention: Investigational (Other)

Outcomes

Primary Outcomes

Infant Behavior Diary

Time Frame: 21 Days

Secondary Outcomes

  • Infant Behavior Questionnaire - Revised(Baseline and Day 21)
  • Recall of Tolerance Questionnaire(Baseline and Day 21)
  • Body Weight(Baseline and Day 21)
  • Recall of formula intake at each visit(Baseline, Day 10, and Day 18)
  • Fecal microbiome and Fecal calprotectin(Baseline and Day 21)
  • Medically-confirmed Adverse Events(21 Days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials